Published in Bioorg Med Chem Lett on February 12, 2010
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis. Br J Pharmacol (2014) 0.77
Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr (2009) 3.66
Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol (2006) 2.62
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol (2005) 2.16
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Multi-parent advanced generation inter-cross (MAGIC) populations in rice: progress and potential for genetics research and breeding. Rice (N Y) (2013) 1.50
Fine mapping of a grain-weight quantitative trait locus in the pericentromeric region of rice chromosome 3. Genetics (2004) 1.40
Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther (2006) 1.37
Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics (2008) 1.27
Response to zinc deficiency of two rice lines with contrasting tolerance is determined by root growth maintenance and organic acid exudation rates, and not by zinc-transporter activity. New Phytol (2010) 1.24
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother (2004) 1.17
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg Med Chem Lett (2006) 1.15
Identification of a histamine H4 receptor on human eosinophils--role in eosinophil chemotaxis. J Recept Signal Transduct Res (2002) 1.11
Functional analysis of RNA binding by the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2005) 1.03
Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold. Bioorg Med Chem Lett (2004) 1.00
Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem (2005) 0.97
Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. J Med Chem (2006) 0.96
New, potent P1/P2-morpholinone-based HIV-protease inhibitors. Bioorg Med Chem Lett (2006) 0.96
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother (2007) 0.94
Gene expression and immunolocalization of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis. Am J Respir Cell Mol Biol (2002) 0.93
Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem Biol Drug Des (2006) 0.92
Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett (2009) 0.92
Pyrazolopyridine antiherpetics: SAR of C2' and C7 amine substituents. Bioorg Med Chem (2005) 0.90
Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. Bioorg Med Chem Lett (2010) 0.87
Human intestinal tissue tropism of intimin epsilon O103 Escherichia coli. FEMS Microbiol Lett (2003) 0.86
High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study. J Acquir Immune Defic Syndr (2008) 0.86
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J Med Chem (2011) 0.85
Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain. J Med Virol (2006) 0.85
Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS One (2008) 0.83
Hepatitis C replication inhibitors that target the viral NS4B protein. J Med Chem (2013) 0.83
Salt-resistant blood pressure and salt-sensitive renal autoregulation in chronic streptozotocin diabetes. Am J Physiol Regul Integr Comp Physiol (2009) 0.83
Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob Agents Chemother (2009) 0.83
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorg Med Chem Lett (2004) 0.82
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. Biochemistry (2004) 0.82
Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties. Bioorg Med Chem Lett (2004) 0.82
Non-steroidal glucocorticoid agonists: the discovery of aryl pyrazoles as A-ring mimetics. Bioorg Med Chem Lett (2007) 0.80
Discovery of next generation inhibitors of HIV protease. Curr Top Med Chem (2005) 0.80
Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. J Med Chem (2008) 0.80
Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist. Bioorg Med Chem (2002) 0.80
Synthesis of HCV replicase inhibitors: base-catalyzed synthesis of protected α-hydrazino esters and selective aerobic oxidation with catalytic Pt/Bi/C for synthesis of imidazole-4,5-dicarbaldehyde. J Org Chem (2013) 0.80
Optimization of pyrrolidinone based HIV protease inhibitors. Bioorg Med Chem Lett (2005) 0.80
Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr (2013) 0.79
[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring. Bioorg Med Chem Lett (2009) 0.79
Rigid 2',4'-difluororibonucleosides: synthesis, conformational analysis, and incorporation into nascent RNA by HCV polymerase. J Org Chem (2014) 0.79
Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors. Bioorg Med Chem Lett (2005) 0.79
Tetrahydrocarbazole amides with potent activity against human papillomaviruses. Bioorg Med Chem Lett (2009) 0.78
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorg Med Chem Lett (2005) 0.78
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. J Med Chem (2013) 0.78
Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists. J Med Chem (2012) 0.78
Substituted tetrahydro-beta-carbolines as potential agents for the treatment of human papillomavirus infection. Bioorg Med Chem Lett (2009) 0.77
Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1. Bioorg Med Chem Lett (2009) 0.77
HIV/AIDS and circumcision: lost in translation. J Med Ethics (2010) 0.76
Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett (2010) 0.76
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate. Bioorg Med Chem Lett (2010) 0.76
Substituted tetrahydrocarbazoles with potent activity against human papillomaviruses. Bioorg Med Chem Lett (2009) 0.76
Capsule endoscopy in the evaluation of gastrointestinal disease. Curr Opin Pediatr (2007) 0.75
The definition of dyslexia. Dyslexia (2002) 0.75
Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism. J Med Chem (2013) 0.75
Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety. Bioorg Med Chem Lett (2003) 0.75
Clinical implications of molecular changes in pediatric Barrett's esophagus. Curr Gastroenterol Rep (2012) 0.75
Essential thrombocythemia presenting as unstable angina pectoris: what should the cardiologist know? Int J Cardiol (2006) 0.75
Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats. Bioorg Med Chem Lett (2011) 0.75
Pyrazolo[1,5-a]pyridine antiherpetics: effects of the C3 substituent on antiviral activity. Bioorg Med Chem Lett (2007) 0.75
Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): modification of the acyl portion. Bioorg Med Chem Lett (2010) 0.75
Realising social justice in public health law. Med Law Rev (2012) 0.75
Discovery of a novel series of cyclic urea as potent CCR5 antagonists. Bioorg Med Chem Lett (2011) 0.75
Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion. Bioorg Med Chem Lett (2010) 0.75
Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses. Bioorg Med Chem (2005) 0.75
Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease. Bioorg Med Chem Lett (2002) 0.75